Legend Biotech's (LEGN) current valuations provide "a buying opportunity," according to analysts at RBC Capital Markets, who said in a note to clients Thursday that the biopharmaceutical company has resolved concerns about its accounting standards and SEC compliance.
The analysts also said Legend's Carvykti is a "best-in-class option" to treat multiple myeloma. "We believe this will continue to drive both patient and physician demand," the analysts wrote. "We see the strength of the data likely supporting successful expansion into earlier lines."
The analysts also said they believe Carvykti has a lot of upside, noting that one-third of doctors haven't heard of the drug.
RBC has an outperform rating on the stock with a $78 price target.
Shares of Legend Biotech were down 1.9% in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。